TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06658902: PATHFNDR-3: Phase 3 Trial of Paltusotine Oral Nonpeptide SST2 Agonist in Carcinoid Syndrome Associated With Neuroendocrine Tumors

Sponsor: Crinetics Pharmaceuticals, Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 190 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06658902 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06658902 Rescue Dossier →